Stockscreener 앱 받기
27.30
0.76%
-0.21
전일 마감가:
$27.51
열려 있는:
$27.45
하루 거래량:
117.23K
Relative Volume:
1.03
시가총액:
$136.47M
수익:
$34.77M
순이익/손실:
$-74.04M
주가수익비율:
-3.4058
EPS:
-8.0157
순현금흐름:
$-79.76M
1주 성능:
-2.22%
1개월 성능:
+171.64%
6개월 성능:
+209.09%
1년 성능:
-44.85%
1일 변동 폭
$27.22
$27.68
1주일 범위
$27.22
$28.05
52주 변동 폭
$5.21
$70.73
Mersana Therapeutics Inc Stock (MRSN) Company Profile
명칭
Mersana Therapeutics Inc
전화
617-498-0020
주소
840 MEMORIAL DRIVE, CAMBRIDGE
MRSN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
27.30 | 137.52M | 34.77M | -74.04M | -79.76M | -8.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-06 | 개시 | William Blair | Outperform |
| 2024-11-15 | 재개 | Citigroup | Buy |
| 2024-03-19 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-29 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-12-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-07-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-07-27 | 다운그레이드 | Truist | Buy → Hold |
| 2023-07-27 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-06-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-06-15 | 개시 | Guggenheim | Buy |
| 2023-03-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-20 | 개시 | Citigroup | Buy |
| 2022-11-21 | 개시 | Truist | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-08-30 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | Credit Suisse | Neutral |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-04-29 | 개시 | BTIG Research | Buy |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-11-14 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
Mersana Therapeutics Inc 주식(MRSN)의 최신 뉴스
Can Mersana Therapeutics Inc. (0M4) stock test all time highsJuly 2025 Macro Moves & Free Reliable Trade Execution Plans - newser.com
Will Mersana Therapeutics Inc. stock outperform Dow Jones indexJuly 2025 Trade Ideas & Safe Capital Growth Stock Tips - newser.com
Can Mersana Therapeutics Inc. (0M4) stock sustain breakout momentumTrade Risk Report & Free High Return Stock Watch Alerts - newser.com
Is Mersana Therapeutics Inc. (0M4) stock testing key supportEarnings Risk Report & AI Driven Stock Reports - newser.com
Will Mersana Therapeutics Inc. (0M4) stock attract long term capital inflowsTrade Entry Summary & Safe Investment Capital Preservation Plans - newser.com
Does Mersana Therapeutics Inc. qualify in momentum factor screeningShort Setup & Low Drawdown Momentum Ideas - newser.com
Why Mersana Therapeutics Inc. stock remains a top recommendationEarnings Miss & Free Reliable Trade Execution Plans - newser.com
Earnings visualization tools for Mersana Therapeutics Inc.2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Will Mersana Therapeutics Inc. stock benefit from infrastructure spending2025 Analyst Calls & Safe Entry Point Alerts - newser.com
How Mersana Therapeutics Inc. (0M4) stock reacts to weak economyTrade Exit Summary & Safe Capital Growth Tips - newser.com
Can Mersana Therapeutics Inc. (0M4) stock stage a strong rebound this quarterEarnings Recap Summary & Capital Efficiency Focused Ideas - newser.com
Detecting price anomalies in Mersana Therapeutics Inc. with AIWeekly Trade Report & Low Risk Entry Point Guides - newser.com
Using data filters to optimize entry into Mersana Therapeutics Inc.Weekly Investment Summary & Low Risk Entry Point Guides - newser.com
Will Mersana Therapeutics Inc. (0M4) stock deliver compounding returnsJuly 2025 EndofMonth & Real-Time Sentiment Analysis - newser.com
Mersana Therapeutics (MRSN) Price Target Decreased by 58.24% to 31.04 - MSN
Wedbush Lowers Earnings Estimates for Mersana Therapeutics - MarketBeat
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results - MarketScreener
Mersana Therapeutics (NASDAQ:MRSN) Posts Quarterly Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc.MRSN - The AI Journal
Lifesci Capital Downgrades Mersana Therapeutics (NASDAQ:MRSN) to Hold - MarketBeat
Mersana Therapeutics (NASDAQ:MRSN) Rating Lowered to "Hold" at Leerink Partnrs - MarketBeat
Mersana Therapeutics Inc (MRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
1.42%
자본화:
|
볼륨(24시간):